Sigma Foods (SIGMAF) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
25 Feb, 2026Business overview and strategy
Operates in 17 countries with over 100 brands and 640,000 points of sale, generating $9.3B in revenue and $1.0B in EBITDA for 2025.
Holds #1, #2, or #3 brand positions in all categories/markets, with strong consumer engagement and innovation capabilities.
Business strategy focuses on growing core categories, exploring new revenue sources, and strengthening organizational capabilities.
Emphasizes health, sustainability, and responsible protein as part of its future growth pillars.
Recent initiatives include corporate identity alignment and ongoing liability management.
Financial performance and guidance
Achieved record 4Q25 EBITDA of $284M, up 28% YoY, with full-year comparable EBITDA of $1.0B, meeting guidance.
Revenue grew 13% YoY in 4Q25, driven by selective price actions, volume growth, and favorable currency translation.
Net debt remained stable at $2.7B with a net leverage ratio of 2.6x at year-end.
2026 guidance targets 2% volume growth, 4% revenue growth, and 5–10% EBITDA growth.
Proposed 2026 dividend of $150M in two installments.
Regional and segment performance
Mexico delivered record revenues and 40% YoY EBITDA growth in 4Q25, led by retail and dairy.
U.S. saw highest 4Q EBITDA (+5% YoY) with Hispanic brands offsetting declines in national brands.
Europe posted 11% YoY revenue growth and 31% YoY EBITDA growth, aided by insurance reimbursements and operational improvements.
Latam achieved record revenue but faced a 12% YoY EBITDA decline due to higher costs and operational challenges.
Latest events from Sigma Foods
- Record 2025 results and Alpek spin-off set up strong 2026 growth and higher dividends.SIGMAF
Q4 202512 Feb 2026 - EBITDA and guidance rose on Sigma's record results, with debt reduction and transformation progressing.SIGMAF
Q2 20242 Feb 2026 - Sigma posts record EBITDA as ALFA advances Alpek spin-off and targets lower leverage.SIGMAF
Q3 202418 Jan 2026 - Record results and transformation position for growth as Alpek spin-off nears completion.SIGMAF
Q4 202419 Dec 2025 - Record revenues and sequential EBITDA gains despite cost and operational headwinds.SIGMAF
Q3 202514 Dec 2025 - Transformation complete, 1Q25 EBITDA at US$220M, S&P upgrades to 'BBB'.SIGMAF
Q1 202529 Nov 2025 - Record 2Q25 revenues and EBITDA, with insurance gains and strategic transformation completed.SIGMAF
Q2 202513 Nov 2025